Research programme: MMP inhibitors - MillenniumAlternative Names: Matrix metalloprotease inhibitors research programme - Millennium; Matrix metalloproteinase inhibitors research programme - Millennium; MMP inhibitors research programme - Millennium; Research programme: matrix metalloprotease inhibitors - Millennium; Research programme: matrix metalloproteinase inhibitors - Millennium
Latest Information Update: 29 Nov 2005
At a glance
- Originator Millennium Pharmaceuticals
- Mechanism of Action Matrix metalloproteinase inhibitors; Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 29 Nov 2005 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 29 Nov 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 29 Nov 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)